Mainspring Recovery, opens new tab, a Virginia-based addiction treatment provider, says its clinical leadership is closely ...

Mainspring Recovery, opens new tab, a Virginia-based addiction treatment provider, says its clinical leadership is closely ...

Between four and 10 million people in the U.S. have fibromyalgia. Many doctors look askance at the disorder, leading some ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, ...

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies. The pattern of inattention, ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Ryan Paige has called Biddeford home his entire life. He grew up in the city, attended its schools and spent time with ...

From online forums to the clinic, people have reported that diabetes and weight-loss drugs such as Ozempic and Wegovy can ...

Substance use disorders are rarely, if ever, isolated concerns. Substance use is often a response to unaddressed mental health challenges, trauma, and unmet needs, and should be treated as such.

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, affecting 12%–13% of adolescents in the United States, according to some studies.

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, drinking and opioid use disorders and addiction.

Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be ...